This product is a second-generation sulfonylurea oral hypoglycemic drug. Its main mechanism of hypoglycemic effect is to stimulate pancreatic beta cells to secrete insulin and partially increase the sensitivity of surrounding tissues to insulin. This product binds to and dissociates from insulin receptors faster than glibenclamide and is less likely to cause severe hypoglycemia.

This product belongs to the class of thiazolidinediones oral antidiabetic drugs, and is a highly selective peroxisome proliferator-activated receptor γ (PPARγ) agonist, which controls blood sugar levels by increasing peripheral and liver insulin sensitivity. Its main mechanism of action is to activate PPARγ nuclear receptors in tissues such as fat, skeletal muscle and liver where insulin acts, thereby regulating the transcription of insulin-responsive genes and controlling the generation, transport and utilization of blood sugar.

It can regulate the physiological function of microvascular walls, reduce plasma viscosity, reduce platelet aggregation and other mechanisms, thereby regulating microcirculation function and playing a role in treating retinal microcirculation lesions caused by diabetes.

It can regulate the physiological function of microvascular walls, reduce plasma viscosity, reduce platelet aggregation and other mechanisms, thereby regulating microcirculation function and playing a role in treating retinal microcirculation lesions caused by diabetes.